Activity-Based Drug Dose Authorization to Preserve Muscle Mass
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for obesity and type 2 diabetes using GLP-1 agonists may cause significant loss of both fat and muscular mass, necessitating a combination with structured physical activity to balance weight loss and preserve lean mass, while the timing and dosage of drug intake are not optimally controlled relative to the user's activity level.
Innovation Solution
A system and method for managing drug dose authorization based on the user's physical activity, using electronic assemblies to track exercise and determine the appropriate timing and dosage adjustments to enhance therapeutic benefits and minimize side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If GLP-1 agonist drug doses are taken to treat obesity and type 2 diabetes, then weight loss and glycemic control are improved, but muscular mass loss occurs as a side effect
Solution Approach 1:
The system performs preliminary action by tracking physical activity before authorizing the next drug dose. It accumulates exercise data and evaluates whether the user has met minimum activity thresholds, then uses this evaluation to control drug dispensing. This ensures that strength training is completed before the next dose, preventing muscular mass loss while maintaining weight loss benefits.
Solution Approach 2:
The system implements feedback by continuously monitoring physical activity levels and using this information to dynamically control drug dose authorization. The exercise tracking data feeds back into the dosing decision process, allowing the system to adjust drug administration based on whether the user has performed sufficient strength training, thereby preventing muscular mass loss.
2Reliability
If drug dosage is increased to enhance therapeutic effect, then glycemic control and weight loss are improved, but side effects increase
Solution Approach 1:
The system applies dynamics by transitioning from static fixed dosing schedules to dynamic activity-based dosing. The drug authorization is no longer based solely on time intervals but adapts in real-time based on physical activity levels. This dynamic approach allows optimal dosing that enhances therapeutic effect while minimizing side effects by considering the user's current physiological state.
Solution Approach 2:
The system changes the dosing parameter from time-based to activity-based control. Instead of administering doses at fixed intervals, the system uses physical activity metrics (such as strength training completion) as the controlling parameter for drug authorization. This parameter change optimizes therapeutic effect while reducing side effects by aligning dosing with physiological responses to exercise.
3Ease of operation
If fixed dosing schedules are used for simplicity, then ease of operation is improved, but therapeutic optimization is reduced
Solution Approach 1:
The system implements self-service by automatically tracking physical activity, evaluating exercise sufficiency, and making dosing decisions without requiring manual user input or complex scheduling by the patient. The exercise tracking and dosing authorization processes are automated, maintaining ease of operation while achieving therapeutic optimization through activity-based control.
Data Source
Figure 1a~1c
Figure 2
Figure 3
AI summary
System (100) for managing the authorisation to proceed with the intake by a user of a dose as a function of the physical activity performed by the user, said system (100) comprising: a first electronic assembly (1) for tracking the physical activity performed by the user; at least one first data processing unit (2) operatively connected to the first electronic assembly (1) for tracking the physical activity performed by the user; at least one first memory unit (3) operatively connected to the at least one first data processing unit (2). The at least one first data processing unit (2) is configured to: compare a value (Q1) of the amount of physical exercise performed by the user, starting from a first instant in time in which a drug dose was taken by the user, with a set reference value (R1), the value (Q1) of the amount of physical exercise performed by the user having been determined, starting from the first instant in time in which a drug dose was taken by the user, as a function of data representative of the physical activity performed by the user traced by said first electronic assembly (1) for tracking the physical activity performed by the user; store in the at least one first memory unit (3) the determined value (Q1) of the amount of physical exercise performed by the user. If the determined value (Q1) of the amount of physical exercise is greater than or equal to the set reference value (R1), the at least one first data processing unit (2) is configured to generate first information (AP-1) representative of an authorisation for the user to proceed with the intake of the next drug dose and to provide the user and/or to personnel qualified to authorise the purchase of the drug with the generated first information (AP-1) representative of the authorisation for the user to proceed with the intake of the next drug dose. If the determined value (Q1) of the amount of physical exercise is lower than the set reference value (R1), the at least one first data processing unit (2) is configured to generate and provide to the user and/or to personnel qualified to authorise the purchase of the drug second information (AP-2) representative of a non-authorisation for the user to proceed with the intake of the next drug dose or not to generate any first information (AP-1) representative of an authorisation for the user to proceed with the intake of the next drug dose.